Holen Sie sich die Stockscreener-App
7.83
1.51%
-0.12
Handel nachbörslich:
7.90
0.07
+0.89%
Schlusskurs vom Vortag:
$7.95
Offen:
$8.01
24-Stunden-Volumen:
667.01K
Relative Volume:
0.26
Marktkapitalisierung:
$546.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-297.11M
KGV:
-1.5087
EPS:
-5.19
Netto-Cashflow:
$-216.95M
1W Leistung:
-13.58%
1M Leistung:
-24.86%
6M Leistung:
+15.32%
1J Leistung:
-28.46%
1-Tages-Spanne:
$7.75
$8.19
1-Wochen-Bereich:
$7.75
$9.14
52-Wochen-Spanne:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
7.83 | 632.52M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
What drives Phathom Pharmaceuticals Inc. stock priceTurbocharged investment results - PrintWeekIndia
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Efficiency Planning - jammulinksnews.com
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Is Phathom Pharmaceuticals Inc. a good long term investmentExceptional trading performance - jammulinksnews.com
Phathom Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough stock performance - jammulinksnews.com
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50 - Defense World
Why Phathom Pharmaceuticals Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
What makes Phathom Pharmaceuticals Inc. stock price move sharplyAnalyst Grade Signals - Newser
How Phathom Pharmaceuticals Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
How To Trade (PHAT) - news.stocktradersdaily.com
Phathom Pharmaceuticals: A Path to Profitability and a Billion-Dollar Horizon with Voquezna? - AInvest
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Holdings Boosted by GAMMA Investing LLC - Defense World
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewswire
Phathom Pharmaceuticals: Stock Awards Driving Shareholder Value to New Heights - AInvest
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update - MarketScreener
Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA - Nasdaq
Phathom Pharmaceuticals Announces FDA Correction to Orange Book - GuruFocus
Phathom Pharmaceuticals (PHAT) Secures Extended Exclusivity for VOQUEZNA | PHAT Stock News - GuruFocus
FDA extends Phathom’s VOQUEZNA exclusivity period to 2032 By Investing.com - Investing.com Canada
FDA Grants 10-Year Exclusivity for Breakthrough GERD Drug VOQUEZNA: Major Win for Phathom - Stock Titan
PHAT Stock Surges: What Investors Need to Know - StocksToTrade
Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade - MSN
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy (PHAT) - Seeking Alpha
Phathom Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Phathom Pharmaceuticals (PHAT) Price Target Increased Following FDA Ruling | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Receives Buy Rating from HC Wainw - GuruFocus
Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals (PHAT) Analyst Rating Update: Price Target Raised to $17.00 | PHAT Stock News - GuruFocus
H.C. Wainwright maintains Buy on Phathom stock, $20 target - Investing.com
Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald - MSN
Zak Mir takes a charting look at the USA Chartbreakers – Saturday 7th June 2025 - Share Talk
Phathom Pharmaceuticals (PHAT) Soars on FDA Approval and Market Exclusivity | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update - GuruFocus
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT - GuruFocus
FDA Grants Phathom Pharmaceuticals (PHAT) Extended Exclusivity f - GuruFocus
Phathom Pharmaceuticals (PHAT) Surges 90% After FDA Grants 10-Year Exclusivity for Voquezna - Wealth Daily
Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity - TipRanks
Phathom Pharmaceuticals (PHAT) Receives Continued Buy Rating fro - GuruFocus
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna - Benzinga
Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna - TipRanks
Needham sees FDA’s positive CP ruling as best-case outcome for Phathom - TipRanks
Phathom Pharmaceuticals Rides High On FDA's Drug Approval - Finimize
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):